SLNO - Soleno Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.8300
+0.4800 (+14.33%)
At close: 4:00PM EST

3.8500 +0.02 (0.52%)
After hours: 6:56PM EST

Stock chart is not supported by your current browser
Previous Close3.3500
Open3.4000
Bid3.7000 x 800
Ask3.8500 x 1200
Day's Range3.4000 - 3.9400
52 Week Range1.1100 - 5.0700
Volume897,030
Avg. Volume270,840
Market Cap170.818M
Beta (5Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.5690
Earnings DateMar 15, 2020 - Mar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
  • 3 Top-Notch “Strong Buy” Stocks Under $3
    TipRanks

    3 Top-Notch “Strong Buy” Stocks Under $3

    If you’re on a budget, yet in a risk-tolerant mood, it’s worth taking a look at penny stocks – companies whose shares sell for less than $5 apiece. Here you get a lot more for your money; For example, buying a single share of Amazon will set you back $1,865, but if you wanted to spend the equivalent amount on a stock worth $3, you could load up on 621 shares of company x.Is it worth it though? Of course, the risk is a lot higher and there’s a chance you could lose the whole investment. Some might not even call it an investment, but rather a speculative shot at massive gains. Still, the possibility of returns is real. While the low price is a put off for some, it could also mean that company x is significantly undervalued and poised to reward the intrepid investor with mighty returns in the future. Like anything else, it’s picking the right one that’s the hard part.Here’s where we call on the pros. TipRanks’ Stock Screener tool was able to filter through thousands of stocks to identify those not only trading under $3 a piece, but also ones which have been making waves on the Street as of late. We found three, that according to the analysts, all show promising signs of making their way out of the penny stocks category and into larger cap territory soon enough. On top of this, each has enormous room for growth, and furthermore, all presently have a “Strong Buy” consensus rating from the Street. Here’s the lowdown.MannKind Corporation (MNKD)Let’s start off with the cheapest stock on our list, MannKind Corporation. Shares of the small-cap biotech are currently selling for $1.51. The diabetes-focused company has a market cap of $312 million, but looking back to the mid 2010’s, MannKind was worth almost $4 billion. So, what happened since then?Bad financial practices combined with underwhelming sales have seen the company lose favor with investors. However, according to Oppenheimer’s Steven Lichtman, MannKind has been steering itself to safety over the last couple of years.Lichtman initiated coverage of MannKind with an Outperform rating and set a price target of $2.50. The figure suggests a possible gain of 66% over the coming months. (To watch Lichtman’s track record, click here)MNKD has one approved FDA treatment on the market: Afrezza. It’s a device which consists of a dry powder formulation of human insulin that is delivered through a portable inhaler. The superfast mealtime insulin’s goal is to improve post-meal glucose control without increasing the risk of hypoglycemia. Although it’s popular with the few who use it, part of its problem has been the lack of insurance for its users. The company has been working with payers and, additionally, new data has helped prescription growth. According to Lichtman, shifting mealtime insulin users away from “tough competitors" towards Afrezza remains key for its success.Lichtman said, “MNKD management has taken steps over the past couple of years to accelerate Afrezza (insulin delivery) sales and diversify using its core Technosphere drug delivery platform. Successes have included continued solid data behind Afrezza and a new partnership with United Therapeutics (UTHR) using Technosphere in UTHR's PAH drugs... While we have not yet seen an inflection in new prescriptions, prescriptions have been steadily increasing, the pipeline around MNKD’s core Technosphere technology has increased and the company's efforts to restructure cash commitments have improved the risk/reward on the shares, in our view.”The Street is currently quiet when it comes to MNKD’s prospects. Those that have been taking note, though, remain bullish on its future. 3 Buy ratings add up to a Strong Buy consensus rating. The average price target is identical to Lichtman’s, $2.50, and therefore also indicates upside potential of 66%. (See MannKind stock analysis on TipRanks) Soleno Therapeutics Inc. (SLNO)This rare disease-focused biopharma had an excellent 2019, adding 72% to its share price along the way. It still only has a $2.85 price per share and market cap of $127 million, but if the analysts on the Street have their way, Soleno will continue its upward trend in 2020 and most likely won’t remain a micro-cap for long.Soleno is currently concentrating on its lead product candidate, DCCR (diazoxide choline controlled-release), a tablet for the treatment of PWS (Prader-Willi Syndrome). The disease is a rare genetic disorder which can cause a wide range of physical symptoms, learning difficulties and behavioral problems. It can also bring on an excessive appetite which can lead to obesity.Oppenheimer’s Leland Gershall believes Soleno has a lot more left in the tank following its rise last year. The 5-star analyst recently initiated coverage on the biopharma with an Outperform rating and set a price target of $10. Should the target be met, investors could pocket gains of 251% in the year ahead. (To watch Gershell’s track record, click here)Leland noted, “DCCR has demonstrated clinical proof-of-concept in PWS, and active ingredient has a long record of human safety. A Phase 3 registration trial will report top-line results in 1H20, for which KOLs are favorable. While the PWS category features several late-stage candidates, our physician consultants regard their distinct mechanisms and delivery formats as providing ample opportunity for each. With just a $65 million enterprise value, we like the risk-reward and recommend building a position ahead of the Phase 3 reveal.”In a similar vein to MannKind, Soleno has three analysts currently tracking its progress, and all are resoundingly effusive. A Strong Buy consensus rating breaks down into Buys only. Upside of 216% could be in the cards should Soleno reach the average price target of $9 over the next 12 months. (See Soleno stock analysis on TipRanks) Marinus Pharmaceuticals, Inc. (MRNS)Marinus is another company with a singular focus and bargain price tag, $2.26 to be exact. The biotech currently has one clinical stage candidate, ganaxolone (GNX), a neuropsychiatric therapy with various indications including epilepsy and other drug resistant neuropsychiatric disorders.In December, the company announced updates from its programs in tuberous sclerosis complex, or TSC, CDKL5 deficiency disorder, or CDD, and PCDH19-related epilepsy. Highlights included data from the PCDH19-related epilepsy Phase 2 trial which showed patients with low levels of allopregnanolone-sulfate (Allo-S) exhibited improved ganaxolone responses. Following the data readout, Marinus performed a biomarker analysis to identify other rare genetic epilepsies that may benefit from the GABAA-receptor modulatory effects of ganaxolone and as a result, announced TSC as the next planned orphan epilepsy program to study the effect of the drug on seizures. Additionally, the company revealed it was granted orphan drug designation by the European Medicines Agency (EMA) for ganaxolone for the treatment of CDD.Oppenheimer’s Jay Olson likes ganaxolone’s clinical data and believes Marinus’ “focused approach” will pay off, calling MRNS a “leader in orphan epileptic disorders.” Olson said, “We are confident in GNX IV development for acute RSE following impressive Phase 2 data with a pivotal Phase 3 trial being planned, in addition to chronic treatment of rare genetic epilepsies currently in pivotal Phase 3 trials with potential for biomarker enrichment. PPD adds potential optionality. We estimate peak revenues of $1.1 billion in 2030.”Therefore, Olson started coverage of MRNS with an Outperform rating and set a price target of $6. What does this indicate, then? Potential upside of an impressive 165%, should the target be met over the coming year. (To watch Olson’s track record, click here)Following the pattern to a T, Marinus receives a Strong Buy consensus rating from the Street consisting of 3 Buy ratings. The average price target comes in at $5.67 and implies potential gains of a considerable 151%. (See Marinus stock-price forecast on TipRanks)

  • Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
    Zacks

    Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

    Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

  • GlobeNewswire

    Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

    Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has completed its target enrollment of approximately 100 subjects in the ongoing Phase III trial, DESTINY PWS, evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS). Additional patients who are currently scheduled to be screened for DESTINY PWS will be enrolled over the next few weeks. “The achievement of target enrollment represents an important milestone for our DESTINY PWS clinical program,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.

  • Do Hedge Funds Love Soleno Therapeutics, Inc. (SLNO)?
    Insider Monkey

    Do Hedge Funds Love Soleno Therapeutics, Inc. (SLNO)?

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 13, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GlobeNewswire

    Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

    Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of its previously announced underwritten public offering of 12,841,667 shares of its common stock, including 1,675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $1.20 per share. The offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-232068) previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”) on July 23, 2019 and a preliminary prospectus supplement filed with the SEC on October 22, 2019 and a final prospectus supplement filed with the SEC on October 25, 2019.

  • GlobeNewswire

    Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock

    Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of 11,166,667 shares of its common stock at a public offering price of $1.20 per share. Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Roth Capital Partners and Laidlaw & Company (UK) Ltd. are acting as co-managers for the offering.

  • Benzinga

    The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 22) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...

  • GlobeNewswire

    Soleno Therapeutics Announces Proposed Public Offering of Common Stock

    Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities described above are being offered by Soleno pursuant to a registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC.

  • GlobeNewswire

    Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has, for the second time, recommended the continuation without modification of the Company’s Phase III trial in Prader-Willi Syndrome (PWS) patients, DESTINY PWS.  The outcome of this second planned meeting was based on the review of data from more than 50% of patients enrolled and treated. “We are pleased to again receive the DSMB’s recommendation to continue the Phase III trial as planned and without modification, which provides ongoing support of DCCR’s safety profile,” said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno.

  • We Think Soleno Therapeutics (NASDAQ:SLNO) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Soleno Therapeutics (NASDAQ:SLNO) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome

    Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the results of the previously completed Phase II trial of diazoxide chloride controlled release (DCCR) for the treatment of Prader-Willi Syndrome (PWS) have been published for the first time in a peer-reviewed journal.  The data are available in the current online edition of PLOS One, a peer-reviewed open access scientific journal published by the Public Library of Science.  The publication is available at https://doi.org/10.1371/journal.pone.0221615.

  • GlobeNewswire

    Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

    REDWOOD CITY, Calif., Sept. 19, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Aug. 07, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • Did Changing Sentiment Drive Soleno Therapeutics's (NASDAQ:SLNO) Share Price Down By 44%?
    Simply Wall St.

    Did Changing Sentiment Drive Soleno Therapeutics's (NASDAQ:SLNO) Share Price Down By 44%?

    Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders will doubtless be very grateful to see the share price up 32% in...

  • GlobeNewswire

    Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome

    Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the Company’s ongoing Phase III trial, DESTINY PWS, evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS). As of July 24, 2019, approximately 50% of the targeted number of patients have been enrolled into the DESTINY PWS clinical study and more than 90% of those patients have either successfully completed or continue to be treated on study.  Over 90% of subjects who have completed the study have elected to continue in C602, the 9-month open-label safety extension study.  More than 95% of the patients who have been enrolled into C602 continue to be treated in the study.

  • Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know
    Zacks

    Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know

    Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
    Zacks

    FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

    The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

  • La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
    Zacks

    La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

    The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

  • GlobeNewswire

    Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors

    Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the appointment of Birgitte Volck, M.D., Ph.D., a veteran biopharmaceutical industry executive, to its Board of Directors, effective June 10, 2019. Dr. Volck’s appointment brings Soleno’s Board of Directors to seven members, six of whom are independent. “We are extremely pleased to welcome Dr. Volck to our Board,” said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno.

  • Will Capnia to Surge Higher?
    Zacks

    Will Capnia to Surge Higher?

    As of late, it has definitely been a great time to be an investor Capnia.

  • What Kind Of Shareholders Own Soleno Therapeutics, Inc. (NASDAQ:SLNO)?
    Simply Wall St.

    What Kind Of Shareholders Own Soleno Therapeutics, Inc. (NASDAQ:SLNO)?

    If you want to know who really controls Soleno Therapeutics, Inc. (NASDAQ:SLNO), then you'll have to look at the...

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results

    REDWOOD CITY, Calif., May 13, 2019 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
    Zacks

    Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

    During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

  • Small Drug Stocks Outlook: Near-Term Prospects Encouraging
    Zacks

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging